ROSEN, SKILLED INVESTOR COUNSEL, Encourages AppLovin Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – APP

Rosen Law Firm is notifying investors in AppLovin Corporation, Beta Bionics, Inc., and Netcapital Inc. about ongoing securities class action lawsuits. AppLovin investors who purchased shares between February 12, 2026 and August 5, 2026 must act by November 16, 2026 deadline. The lawsuit alleges AppLovin made false statements about AI video features, overstated AI model improvements, and misrepresented the benefits of its AI platform's 'virtuous cycle' value proposition.

10/21/2026, 8:50 PM • GlobeNewswire

BBNX DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (BBNX) alleging that the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The lawsuit claims thousands of complaints were filed with the FDA, contrary to defendants' assertions that they were benign. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

10/21/2026, 7:36 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding the safety and regulatory compliance of its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose FDA observations about quality management system deficiencies and underreported serious customer complaints. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.

10/21/2026, 1:00 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose serious safety deficiencies and customer complaints, understating regulatory risks and safety concerns during the period from July 30, 2025 to February 24, 2026.

10/18/2026, 1:00 PM • GlobeNewswire

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Lincoln Educational Services Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - LINC

Rosen Law Firm is encouraging investors who purchased securities of Lincoln Educational Services (LINC), AST SpaceMobile (ASTS), and Beta Bionics (BBNX) during specified class periods to join securities class action lawsuits. The firm reminds investors of important lead plaintiff deadlines and notes that class actions have already been filed alleging false and misleading statements by defendants.

10/18/2026, 5:58 AM • GlobeNewswire

BBNX DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The lawsuit claims thousands of complaints were filed with the FDA, contrary to defendants' assertions that they were benign. The lead plaintiff deadline is November 3, 2026.

10/18/2026, 12:25 AM • GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Baidu, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIDU

Rosen Law Firm is reminding investors in Baidu, Inc., AST SpaceMobile, Inc., and Beta Bionics, Inc. about upcoming deadlines to join securities class action lawsuits. The lawsuits allege that these companies made false or misleading statements regarding their business operations and financial prospects. Investors who purchased securities during specified class periods may be eligible for compensation.

10/18/2026, 12:25 AM • GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Tigo Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TYGO

Rosen Law Firm is reminding investors in Tigo Energy, AST SpaceMobile, and Beta Bionics of upcoming deadlines to join securities class action lawsuits. The firm alleges that Tigo Energy made false revenue projections based on an EG4 partnership that would not materialize until Q4 2026 at the earliest, resulting in materially misleading statements about the company's business and prospects.

10/18/2026, 12:24 AM • GlobeNewswire

ROSEN, A LONGSTANDING FIRM, Encourages AppLovin Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – APP

Rosen Law Firm has filed securities class action lawsuits against AppLovin Corporation, Lincoln Educational Services Corporation, and Beta Bionics, Inc. The AppLovin lawsuit alleges the company made false statements regarding AI video creative features and overstated the benefits of its AI models. Investors who purchased securities during specified class periods are encouraged to seek counsel before upcoming lead plaintiff deadlines.

10/15/2026, 7:09 PM • GlobeNewswire

BBNX DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Rosen Law Firm is notifying Beta Bionics, Inc. investors of a November 3, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false statements about its iLet Bionic Pancreas insulin pump, which the FDA found to be malfunctioning and causing dangerously high insulin dosing. The company allegedly failed to implement meaningful corrective actions despite thousands of complaints and hundreds of life-threatening events.

10/15/2026, 6:28 PM • GlobeNewswire

Beta Bionics, Inc. Class Action Reminder - Robbins LLP Encourages BBNX Investors to Contact the Firm for Information About Their Rights

Robbins LLP reminds investors of a class action lawsuit against Beta Bionics (BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company failed to disclose serious FDA concerns about device malfunctions causing dangerously high insulin doses and hypoglycemic events. Stock fell from $31.99 to $12.89 per share between January and February 2026 following FDA warning letter disclosures.

10/14/2026, 6:42 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Beta Bionics, Inc. for alleged securities fraud. The complaint alleges that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump, including undisclosed quality management deficiencies and unreported serious customer injuries. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.

10/14/2026, 1:00 PM • GlobeNewswire

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels causing hypoglycemic events, and that the company failed to disclose thousands of complaints to the FDA. Investors who purchased stock between July 30, 2025 and February 24, 2026 can apply to be lead plaintiff by November 3, 2026.

10/13/2026, 11:45 PM • GlobeNewswire

AEVEX Corp. Notice of October 20, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC announces class action securities lawsuits against AEVEX Corp., Beta Bionics, Inc., and York Space Systems, Inc. The primary case alleges that AEVEX and its executives concealed a pre-arranged plan to prematurely override a 180-day lock-up commitment, allowing Madison to sell shares and generate over $200 million through a secondary offering. Investors who purchased shares during the class periods have until the specified deadlines to request lead plaintiff status.

10/13/2026, 11:24 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX

Pomerantz Law Firm has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud related to its iLet insulin pump device. The company allegedly misrepresented FDA concerns and failed to properly report thousands of patient complaints. The lawsuit follows significant stock price declines after the FDA issued a warning letter in February 2026, revealing more serious safety and reporting issues than Beta Bionics had previously disclosed. Investors have until November 3, 2026, to join the class action.

10/13/2026, 4:52 PM • GlobeNewswire